Skrofuloderma

01Pathophysiology

Scrofuloderma is a form of cutaneous tuberculosis that arises not from direct inoculation through the skin but from contiguous extension of an underlying tuberculous focus into the overlying skin. This distinction is central to understanding the disease and differentiating it from other forms of cutaneous TB.

The process begins with an established focus of Mycobacterium tuberculosis infection in a deep structure, most commonly the cervical lymph nodes (tuberculous lymphadenitis, or scrofula). Other common underlying foci include bones and joints (tuberculous osteomyelitis or arthritis), the epididymis, and, less frequently, the lacrimal gland or breast tissue. The bacilli within these deep structures trigger a granulomatous immune response characterized by caseating necrosis. As the caseous material accumulates, the expanding necrotic zone erodes through the subcutaneous fat, dermis, and epidermis in an outward trajectory.

The overlying skin initially shows a firm, painless, subcutaneous nodule that becomes adherent to the skin surface. This adherence is the clinical clue that the pathology originates from below, not within the skin itself. The skin overlying the nodule gradually turns dusky or violaceous as the blood supply is compromised by the expanding granulomatous process beneath. Eventually the nodule softens, becomes fluctuant, and breaks down to form ulcers with sinus tracts that discharge watery, purulent, or frankly caseous material.

The ulcers characteristically have undermined, bluish edges, a finding that reflects the ongoing destruction of subcutaneous tissue at the periphery of the lesion while the skin edge hangs over the crater. This undermining is a hallmark feature and a frequently tested physical exam finding.

Healing, when it occurs (either spontaneously or with treatment), produces irregular, cord-like, or bridging (retracted) scars. These scars are distinctive because the skin bridges across areas of tissue loss, creating bands of fibrosis interspersed with areas of normal skin. Recognizing these scars in a vignette can point toward a prior or chronic scrofuloderma process.

Because the patient has moderate cell-mediated immunity, they mount enough of an immune response to form granulomas but not enough to contain the infection entirely. This is why the tuberculin skin test is typically strongly positive in scrofuloderma patients, in contrast to patients with miliary TB or orificial TB who are often anergic.

02Classification and Clinical Manifestation

Cutaneous TB Classification (Contextualizing Scrofuloderma)

Stages of Scrofuloderma Lesion Evolution

Common Sites of Involvement

03Diagnostic Workup

The diagnostic approach to scrofuloderma follows a layered strategy that moves from clinical suspicion and screening to tissue-based confirmation.

Step 1: Establish clinical suspicion. A young patient from a TB-endemic region presenting with a painless subcutaneous nodule or draining sinus overlying a lymph node group should immediately raise the suspicion for scrofuloderma. The physical exam findings of undermined bluish ulcer margins and caseous discharge are highly suggestive.

Step 2: Screening tests. The tuberculin skin test is the best initial test to support your suspicion. A strongly positive result (typically >15 mm) is expected because scrofuloderma patients maintain moderate cell-mediated immunity. However, TST cannot distinguish active disease from latent TB or prior BCG vaccination. In BCG-vaccinated populations, the IGRA (QuantiFERON-TB Gold) is preferred because it uses antigens (ESAT-6, CFP-10) not present in the BCG vaccine, thus reducing false positives.

Step 3: Evaluate for systemic TB. A chest X-ray should be obtained in every patient to look for concurrent pulmonary involvement. The presence of pulmonary findings strengthens the diagnosis and changes the management context. Consider additional imaging (ultrasound or CT) of the underlying focus to confirm the deep-seated origin, such as a tuberculous lymph node or bone lesion.

Step 4: Tissue confirmation. A punch or excisional biopsy of the skin lesion is the critical step. Histopathology classically shows caseating granulomas composed of epithelioid histiocytes, Langhans-type multinucleated giant cells, and a rim of lymphocytes surrounding a central zone of caseous necrosis. This pattern is the histopathologic hallmark. A Ziehl-Neelsen stain on the biopsy specimen may reveal acid-fast bacilli, though sensitivity varies.

Step 5: Definitive identification. Mycobacterial culture on Lowenstein-Jensen medium or in an automated liquid culture system (BACTEC) is the gold standard because it provides both species identification and drug susceptibility testing. The major drawback is the prolonged incubation time. PCR for M. tuberculosis offers a rapid alternative with high sensitivity, and is particularly valuable when you need to start treatment before culture results return. The combination of a positive biopsy showing caseating granulomas plus a positive PCR or culture is considered definitive.

04Management and Treatment

Drug Doses (Adults)

Acute stabilization and the first-line regimen. The cornerstone of scrofuloderma treatment is standard anti-tuberculous chemotherapy, identical to the regimen used for pulmonary TB. Treatment is initiated as soon as the clinical and laboratory picture supports the diagnosis; you do not need to wait for culture results before starting therapy. The intensive phase uses all four first-line drugs (RHZE) for two months to rapidly reduce the bacterial load, followed by a continuation phase of two drugs (RH) for four months to eliminate persisting organisms.

Pyridoxine (Vitamin B6) supplementation at 25 to 50 mg/day is routinely given alongside isoniazid to prevent peripheral neuropathy, especially in patients with additional risk factors (diabetes, HIV, malnutrition, pregnancy, alcoholism).

Monitoring during treatment. Liver function tests (AST, ALT, bilirubin) should be checked at baseline and periodically during the first two months, as isoniazid, rifampicin, and pyrazinamide are all hepatotoxic. If transaminases rise to more than 3 times the upper limit of normal with symptoms, or more than 5 times without symptoms, the regimen must be held and reintroduced sequentially. Visual acuity and color vision should be monitored for patients on ethambutol.

When to extend treatment. If the underlying focus is bone or joint TB, the total treatment duration is extended to 9 to 12 months because skeletal TB requires a longer continuation phase to achieve adequate tissue penetration and sterilization.

Surgical considerations. Incision and drainage of fluctuant abscesses or excision of persistent sinus tracts may be needed as an adjunct to medical therapy, particularly when lesions fail to respond to chemotherapy alone. Surgery is never a substitute for anti-TB drugs.

Contraindications and adjustments.
Pyrazinamide is contraindicated in patients with severe hepatic impairment and should be used cautiously in patients with gout or hyperuricemia. In pregnancy, pyrazinamide is avoided by some guidelines (notably those from the United States) due to insufficient safety data, and the regimen is modified to isoniazid, rifampicin, and ethambutol for a longer total duration (9 months). Streptomycin is contraindicated in pregnancy due to ototoxicity to the fetus. In renal failure, dosing intervals for ethambutol and pyrazinamide are adjusted based on creatinine clearance, while isoniazid and rifampicin require no renal dose adjustment.

Response assessment. Clinical response is expected within 1 to 2 months, with reduction in discharge and gradual healing of sinuses. Failure to improve after 2 to 3 months of compliant therapy should prompt reassessment for drug-resistant TB, an alternative diagnosis, or a retained foreign body/sequestrum in the underlying bone.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on scrofuloderma questions is by confusing it with other forms of cutaneous TB, especially lupus vulgaris. Both are chronic, both are granulomatous on biopsy, and both test positive on TST. The critical discriminator is the mechanism of skin involvement: scrofuloderma arises from contiguous spread from a deep underlying focus (a lymph node or bone lesion directly beneath the skin), while lupus vulgaris arises from hematogenous or lymphatic dissemination and presents as a plaque, not a draining sinus. If the vignette describes a nodule that is fixed to an underlying structure and breaks down into a sinus tract, that is scrofuloderma. If it describes a red-brown plaque with apple-jelly nodules on diascopy, that is lupus vulgaris.

Another common trap involves the diagnostic sequence. Students may jump directly to culture or PCR without first recognizing that the best initial test is the tuberculin skin test (or IGRA in BCG-vaccinated populations), followed by biopsy. The gold standard for definitive confirmation remains mycobacterial culture, not biopsy alone, because culture provides species identification and drug susceptibility data. Getting this sequence wrong is a frequently exploited testing point.

A third pitfall is forgetting to screen for pulmonary TB. Scrofuloderma signals the presence of a deep-seated TB focus, and a significant proportion of these patients have concurrent pulmonary disease. A chest X-ray is always indicated, and overlooking it in the workup is a testable oversight.

Finally, be alert to the treatment duration trap. Standard cutaneous TB is treated for 6 months. However, if the underlying focus involves bone or joint, the total duration extends to 9 to 12 months. A vignette describing scrofuloderma overlying a vertebral lesion (Pott disease) that asks for the appropriate treatment length is testing whether you adjust for skeletal involvement. The correct answer in that scenario is the extended regimen, not the standard 6-month course.

The core competency being tested with scrofuloderma is your ability to recognize that the skin findings are a surface manifestation of a deeper process, to correctly sequence the diagnostic workup from screening to confirmation, and to match the treatment duration to the underlying focus.